A flooded healthcare AI market prompts confusion

The AI conundrum: Having too many options adds to complexity

The healthcare AI market has reached a tipping point. Solutions are far from scarce. From ambient clinical documentation and revenue cycle automation to prior authorization tools and patient engagement platforms, the application of AI across healthcare workflows has grown consistently alongside innovation.

Physicians, their clinical teams, and staff are beginning to feel that impact, particularly in reducing administrative burden and reclaiming time during the clinical day.¹ But for many healthcare leaders, that progress has introduced a new challenge: the pace of innovation has outstripped the ability to evaluate it.

Too many vendors. Too many overlapping claims. Too much uncertainty around cost, governance, and ROI. What should feel like opportunity often feels like risk.

The result is a paradox: more AI solutions are entering the market, but adoption concerns also rise when evaluation becomes more complex.

For organizations operating under staffing constraints and limited IT bandwidth, the question has become how to determine which solutions are worth adopting—and whether their technology partners can support that decision with confidence.

AI innovation in healthcare is accelerating — but so are some adoption barriers

Over the past five years, healthcare AI has expanded rapidly across both clinical and administrative functions. The proof is in the numbers. AI spending in healthcare tripled year-over-year from 2024 to 2025, reaching $1.4 billion.² Of the 1,357 AI medical devices authorized by the Food & Drug Administration (FDA) in the last decade, more than half were added in the last three years.³

But this acceleration has introduced a new layer of complexity. Many vendors offer compelling demonstrations but may lack consistent validation. Others provide limited transparency into how models are trained, updated, or governed over time. At the same time, regulatory frameworks are still evolving, leaving organizations without standardized benchmarks for evaluating safety and performance.

Hesitations extend beyond product impact and performance. The speed with which the healthcare AI market has evolved makes product longevity and durability difficult to measure. There are no guarantees when it comes to the ability for chosen vendors to sustain innovation or remain competitive.

While access to innovation has increased, the ability to assess its impact has grown increasingly more difficult. Healthcare leaders feel overwhelmed by the number of options at their disposal, not to mention balancing financial feasibility and understanding whether AI tools can help deliver clear ROI.⁴

That creates a new tension for healthcare organizations: long-term contracts can feel misaligned with the pace of change, but continuously re-evaluating vendors year after year introduces its own operational burden.

In practice, evaluating healthcare AI now requires answering three difficult questions at once:

• Will this work within our specific specialty and patient population?
• How will it integrate with our existing systems and workflows?
• Can we forecast and measure ROI without introducing new operational burdens?

Cost structure further complicates the equation. Licensing fees are only one part of the picture. Integration work, training, monitoring, and ongoing optimization all contribute to total cost of ownership. Those factors are often difficult to quantify upfront.

Why a crowded vendor landscape can lead to delayed decisions

Many AI tools are deployed as point solutions, requiring clinicians and staff to navigate additional systems, duplicate work, or adjust established workflows. Even small disruptions can accumulate, reducing adoption and limiting long-term value.

At the same time, trust remains a barrier. Without clear evidence of outcomes, practices are left weighing vendor claims against operational risk. This uncertainty rarely results in decisive action. Instead, it shows up in more subtle ways: extended procurement cycles, pilots that never scale, or a default decision to wait for more mature solutions.

Locking into a multi-year agreement with a rapidly evolving AI vendor can feel risky, particularly when product capabilities — and even market leaders — may shift significantly within that timeframe. This dynamic often reinforces a “wait and see” approach, even when the potential value of AI is clear.

In many organizations, that decision – or indecision – typically results in waiting for an EHR vendor to help deliver something integrated. That instinct reflects a deeper need not just for AI tools, but for a coherent, trusted path to adopting them.

How to evaluate AI vendors without getting lost in demos

To move forward, leading organizations should consider shifting away from feature-based comparisons and toward outcome-based evaluation. Through that lens, the focus becomes whether AI can demonstrably affect meaningful changes.

This shift often starts with a simple reframing: instead of asking vendors to present capabilities, practices define the outcomes they need to achieve. Those outcomes might include reducing time spent on documentation, improving first-pass claim acceptance rates, or increasing patient access.

A vigilant approach can also help mitigate long-term risk. By prioritizing measurable outcomes and structuring evaluations around defined pilot periods, organizations can avoid overcommitting to vendors before value is proven while also reducing the need for repeated, resource-heavy selection cycles.

From there, evaluation becomes more disciplined. Vendors are asked to demonstrate performance within real workflows, not controlled demo environments.

Governance also moves to the forefront. Understanding how models are trained, monitored, and updated — and how data is handled — becomes just as important as functionality. And perhaps most importantly, practices establish clear success criteria for pilots, along with defined exit points if those criteria are not met.

When done well, this approach shifts AI adoption from a speculative investment to a measurable operational decision.

Considerations for choosing an AI-enabled technology partner

As practices evaluate potential partners, they may be incentivized to determine how the broader platform strategy can support them. 

In a rapidly shifting market, platform stability becomes just as important as innovation. Partners that can continuously evolve their AI capabilities within an existing ecosystem may help organizations avoid the cycle of repeated vendor selection and replacement. 

Effective partners will likely share a few defining characteristics: 

• They embed AI directly into core clinical and administrative workflows
• They provide flexibility through integrated, specialty-specific solutions
• They support pilot-based validation within real-world environments
• They offer transparent governance and model monitoring
• They leverage network-scale data to continuously improve performance 

These elements can help determine whether AI adoption will scale successfully or stall after initial implementation. The characteristics above might also explain recent research suggesting EHR vendors have an advantage over third-party solutions when it comes to integration and implementation at scale.⁵ 

That said, even if EHR vendors have a leg up, this might invoke questions and a deeper evaluation of organizational needs for AI implementation – and whether existing partners are equipped to meet those needs.

A vigilant approach can also help mitigate long-term risk. By prioritizing measurable outcomes and structuring evaluations around defined pilot periods, organizations can avoid overcommitting to vendors before value is proven while also reducing the need for repeated, resource-heavy selection cycles.

The athenahealth approach to AI adoption 

athenahealth’s approach is grounded in a simple principle: AI should support how practices already work, not require them to start over. 

Within athenaOne®, AI capabilities are embedded directly into clinical and administrative workflows, helping organizations realize value without introducing unnecessary disruption. This includes AI-native capabilities across documentation, revenue cycle, and patient engagement, supported by an Advanced Intelligence Layer that enables secure deployment, monitoring, and continuous improvement. 

Additionally, athenahealth provides optionality through the Marketplace, where practices can adopt specialized solutions that integrate seamlessly into the existing platform. This allows organizations to extend capabilities without fragmenting their workflows or introducing additional systems. 

Just as importantly, practices can adopt AI incrementally. Through alpha and beta programs, organizations can test new capabilities, validate impact within their own environments, and expand adoption based on measurable results. 

In practice, this helps create a more controlled and sustainable path to AI adoption to balance innovation with operational stability. 

Navigating the healthcare AI landscape with confidence 

AI is transforming healthcare, but it is also making certain decisions more complex. 

For many organizations, hesitation is not a sign of resistance. It reflects the stakes involved. Cost, trust, workflow impact, and long-term sustainability all factor into the decision. The path forward is about prioritizing clarity over speed.

athenahealth is positioned to help practices navigate this complexity by combining embedded AI capabilities with the flexibility to extend those capabilities through a curated Marketplace. The goal is not simply to introduce AI, but to make it work in the environments where care is delivered every day. 

Ready to cut through the AI noise? Discover how athenahealth’s integrated AI solutions can help deliver results without the complexity. Schedule a consultation to see how our AI-native platform can address your specific practice needs.